Bio-Me has appointed a new CEO as part of the company’s strategic plan to be positioned as a leader in the microbiome-based Precision Medicine space....
Our COO, Warren Flood, will be participating in a webinar together with Thermo Fisher Scientific on September 22nd with a focus on our PMP™ technology and its applicability....
Bio-Me has announced a major board restructuring that will support the Company during its new phase of development....
Bio-Me has been invited to present at the upcoming Microbiome Movement - Drug Development Summit. ...
Bio-Me and Akershus University Hospital aim to explore gut microbiome profiles linked to long-term effects of COVID-19....
Bio-Me today announced that it has successfully raised NOK 10 mill in a fully subscribed funding round. Both existing and new investors participated in the financing round, with new investors contributing to the majority of the capital....
Bio-Me and Siolta Therapeutics aim to develop and market predictive test for infants.
...
Bio-Me today announced that a new Board of Directors has been approved by the general assembly.
...
Runar Vige has taken on the role of Chief Clinical Officer. Runar brings more than 20 years of broad interdisciplinary experience working with companies like Pfizer, Pronova BioPharma, and BASF.
...
Bio-Me has received 2 million Euro in grants and public support from The Research Council of Norway to develop a companion diagnostic test for immune checkpoint inhibitor cancer treatments.
...
